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A lot of people were affected with COVID-19, and it has an obvious effect on the heart.
There are many cardiovascular complications of corona virus disease. Myocardial
infarction is one of the diseases that can be caused by this virus and it is common among

Keywords

those patients. As well as, echocardiographic changes are found in COVID-19 patients
like ST elevation that may resemble that of MI. However, the incidence of MI decreased

•

COVID-19

•

Cardiovascular

during this pandemic due to many causes including the fear of the patients from catching

system

the infection from the hospitals. In addition to that, there are many mechanisms that can

•

Myocardial injury

lead to MI in those patients, including cytokine storm. Elevated cardiac troponin in

•

ST elevation

COVID-19 patients may indicate type 2 MI or type 1 but it has a prognostic value. The

Myocardial

management didn’t change a lot during the pandemic in comparison to before it,
however personal protective equipment is very important to protect the medical stuff
from the virus.
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INTRODUCTION

coronavirus

Millions of people all over the world have been

(cardiovascular) system.

infected by Coronavirus disease 2019 (COVID-

The virus

19)(Center., 2020).This virusmainlyaffects the

COVID-19 is caused by SARS-CoV-2, which is

respiratory system. However, the cardiovascular

nearly like the SARS-CoVvirus(Atri et al.,

system can been also disrupted(Shaobo Shi et

2020). Its transmission was thought to be from

al., 2020; D. Wang et al., 2020; F. Zhou et al.,

bats that actas a natural reservoir throughan

2020).

intermediate animal host(Atri et al., 2020).Body

This novel virus can affect the cardiovascular

cells are invaded by this virus through the

system

and

binding of spike (S) glycoprotein of the virus to

indirect(Tortorici & Veesler, 2019; Xia et al.,

ACE2 ( angiotensin-converting enzyme 2)

2020).These complications are notonly common,

receptors(Hoffmann, Kleine-Weber, Krüger, et

but also have a bad prognostic value(Xia et al.,

al., 2020).

2020).

Since the Spanish flu of 1918, this outbreak has

During the pandemic, the rate of admission

the highest mortality rate(F. Zhou et al.,

because of acute myocardial infarction was

2020).Patients

clearly decreased. Myocardial infarction is one

problems are infected more with coronavirus

the most severe extra-pulmonary complication

and the disease in those individuals is more

which affects cardiac patients as well as people

critical. The impact on the heart is by direct and

who carry risk factors of cardiac diseases (De

indirect ways, as well as it can interact with CV

Rosa et al., 2020).

drugs.Furthermore,cardiac care for the people

in

both

ways:

direct

disease

with

2019

and

the

cardiovascular

CV

(CV)

ST-elevation is a common finding in

who are not COVID positive is affected due to

patient with COVID-19 due to either obstructive

the broad impacts of the outbreak on health

or non-obstructive causes. It can also happen

services (F. Zhou et al., 2020).

even

coronary

Transmission is by self-contamination of the

angiography(Bangalore et al., 2020; Inciardi et

eyes, nose, or mouth after touching infected

al., 2020).The morbidities and the mortalities

objects or inhaling droplets from a patient and it

clearly increased in cardiac patients with

also can be transmitted from carriers ( those who

COVID-19 infection(Inciardi et al., 2020).

have no symptoms)(Prevention., 2020).

Aim of work

There are many phases in the coronavirus

The aim of this work is to make a summary

disease course (Siddiqi & Mehra, 2020).Starting

about the present information of COVID-19,

with just constitutional manifestations, and the

giving an attention on the relation between the

most characteristics are fever and cough. In the

on

top

of

normal

next phase, there aredirect viral cytotoxiceffects,

https://mmj.mans.edu.eg/home/vol50/iss4/4
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especially in the respiratory tract, resulting

mortality rate was 6 times more in people with

inrespiratory failure and as a consequenceacute

elevated troponin that those without (T Guo et

respiratory distress syndrome (ARDS). The last

al., 2020). As well as, cardiac patients with high

one

troponin had higher mortality, on the other hand,

is

suspected

hyperinflammatory

to

response

be
to

due

toa

the

viral

those

with

normal

levels

particlesresulting in effects allover the body

betteroutcome,although

systems, including the CVsystem(Siddiqi &

individuals without heart diseases or increased

Mehra, 2020).

troponin(T Guo et al., 2020).

more

than

AMI (acute myocardial infarction) may be

Cardiovascular complications of coronavirus

asignificantindicator of illness seriousness and

disease

It

still

hada

1. Acute cardiac injury

poor outcome in coronavirus disease 2019.

is

Despite that, the mechanisms of this are not

expressed by high troponin, ECG
myocardial

clear and they are mostly due to many

dysfunction, and it is common in some groups of

causes(Figure 1). Plausibleetiologies to acute

individuals with coronavirus disease 2019 in

cardiac injury in coronavirus patients include (1)

hospitals(S Shi et al., 2020).

sudden changes in the demand and supply of the

(echocardiography)

It

is

reported

changes, or

that

high-sensitivity

myocardium due to increased heart rate,

cardiactroponin I (hsTnI) is more in patients

decreased blood pressure,and low oxygen level

who did not survive than in survivors (Guo, Fan,

in blood leading to type 2 MI;(2) ACS; (3)

& Chen, 2020). As well as, there was a pattern

microvascular

of rising high-sensitivity cardiactroponin I in

diffusemicrothrombi or vascular injury; (4)

nonsurvivors at day 13 from the beginning of the

stress-related cardiomyopathy; (5) nonischemic

disease,whileit stayed normal in survivors. This

myocardialinjury due to a cytokine storm;or (6)

provedthat the etiology of the injury in acute

direct

coronary syndrome (ACS) is acute inflammatory

myocarditis(Atri et al., 2020)(figure 1).

viral

dysfunction

cardiomyocyte

due

toxicity

to

and

condition(T Guo et al., 2020).
In addition to that, there was a direct proportion
between the mortality rate and the amount of
troponin increase(T Guo et al., 2020).The

Published by Mansoura Medical Journal, 2023
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Figure 1: Mechanisms of AMI related to coronavirus disease 2019. (Atri et al., 2020)

2. Myocarditis and pericarditis
They are

common CV

coagulation profiles of people admitted to the

complications

of

coronavirus disease 2019 (Inciardi et al., 2020).
3. Heart failure and cardiogenic shock

hospital with coronavirus disease 2019 with
significant high D-dimer (D. Wang et al., 2020;
F. Zhou et al., 2020).

They are significant causes of death in this viral

Patients who did not survive had anobvious

disease.Approximately one third of mortalities

increase in D-dimer during thecourse of the

wasdue to respiratory and heart failure, while

illness(F. Zhou et al., 2020). On admission, they

only 7% was due to heart failure alone(Ruan,

had high D-dimer and FDPs (fibrin degradation

Yang, Wang, Jiang, & Song, 2020). Myocarditis

products),lately, most of them had disseminated

is thought to be the cause of the heart failure,

intravascular coagulation (DIC)(Tang, Li, Wang,

and it is considered that inflammatory condition

& Sun, 2020).

and cytokine storm are the main mediators of

Moreover,antiphospholipid

heart failure in coronavirus patients(Siddiqi &

reported to be present and also multiple cerebral

Mehra, 2020). Thatis due to thesignificantly

infarctions(Zhang et al., 2020).

increased inflammatory markers inthose with

Thus,

serious coronavirus disease 2019 (F. Zhou et al.,

thromboembolism should be given to all

2020).

coronavirus patients, as well as they should take

4. Thrombosis

and

venous

are

concerned

recently

anticoagulants

for

against

already

were

venous

formed

thromboembolisms(Schünemann et al., 2018).

thromboembolic disease
Doctors

prophylaxis

antibodies

about

5. Arrhythmias

thromboembolism in coronavirus disease 2019.

Less than one fifth of people with coronavirus

It is reasonable thatCOVID-19 infection also

had arrhythmias, specifically supraventricular

increases venous thromboembolism probability,

tachycardia and it is more prevalent in intensive

this is due to the alterations seen in the

care unit (ICU)(D. Wang et al., 2020). On the

https://mmj.mans.edu.eg/home/vol50/iss4/4
DOI: 10.21608/mjmu.2021.83010.1023
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other hand, patients with high blood levels of

abnormality in the angiography, and this can

cardiac troponin had more commonly severe

indicateinflammation

arrhythmias like ventricular tachycardia and

myopericardium(Nicola Gaibazzi, Martini, &

ventricular fibrillation (T Guo et al., 2020).

Mattioli, 1990).Wide varieties of ST segment

Echocardiographic findings in COVID-19

elevation can beseen in COVID-19 patients and

patients

it may be due to myocardial infarction or

Diffuse or focal ST elevation may simulate ST

not(Bangalore et al., 2020)(figure 2 and 3).

elevation

myocardial

infarction

with

of

the

no

Figure 2:ST elevation but not due to an actual myocardial infarction in a coronavirus patient.(Nicola Gaibazzi et al., 1990)

Figure3:an actual inferior ST elevation myocardial infarction in a patient with coronavirus disease 2019.(Nicola
Gaibazzi et al., 1990)

Incidence of myocardial infaction with COVID-19
During this outbreak in Italy, the number of

in the pandemic in comparison to the same time

hospitalized patients due to acute myocardial

of the last year were halved (De Rosa et al.,

infarction showed a dramatic decline. Indeed,

2020)(figure 4).

admitted patients for acute myocardial infarction

Figure 4:Admissions for AMI during the pandemic.(De Rosa et al., 2020)

Published by Mansoura Medical Journal, 2023
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This is precipitated by many etiologies. First,

start of social gathering, so this is another cause

patients were afraid of catching the infection

of less AMI admissions(C. K. Tam CF, Lam S,

from the hospitals thus they decrease their visits

et al. , 2020 Apr;).

to

,

Also, it is pointed out that the duration from

especially after the media declared that there is

FMC (first medical contact) to coronary

lack of PPE (personal protective equipment) and

revascularization

waslargely

as a result of that, the novel virus affected many

individuals

ST

patients as well as many staff members(Indolfi

infarction (STEMI). This is so essentialas

& Spaccarotella, 2020).

primary Percutaneous coronary intervention

Anotherthesis is related to the focus of the

(PPCI)andreperfusion

medical system on the pandemic, so most of the

important, but not enough: therefore efficient

hospital resources and members were busy

care pathway in order tofacilitate the steps for

managing it. In line with that, the decrease in

those patients is very important(Stehli J, 2019).

hospitalizationsof

myocardial

In that regard, there is amajor risein case

infarction was less than that of non ST elevation

fatalities and complications detected in this

myocardial infarction(Indolfi & Spaccarotella,

outbreak(De Rosa et al., 2020)(figure 5). Thus,

2020).

approximately 50% of these patients do not

As well,acute CVdiseases incidence is truly

arrive at the hospital, thus deaths and heart

reducedand this is due to low physical

failure due to acute myocardial infarction will be

stressduring the quarantine,particularly at the

considerably more(Cosentino N, 2020).

EMS

(emergency

ST

medical

elevation

services)

with

increased

elevation

in

myocardial

medications

are

Figure 5: Case fatality rate for AMI. (De Rosa et al., 2020)

Impact of COVID-19 pandemic on patients

era. The cardiac troponin-1 (cTn-1)levels on

presenting with STEMI

admission was also remarkably higher in the

During the pandemic, the duration between

COVID era versus before it (Abdelaziz HK).

symptoms presentation and first medical contact

The prognosis of ST elevation myocardial

was greatly delayedcompared to pre-COVID

infarction (STEMI) depends mainly on the

https://mmj.mans.edu.eg/home/vol50/iss4/4
DOI: 10.21608/mjmu.2021.83010.1023
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duration of ischemia, and to decrease the

essential, however this may lead to more

mortality and morbidity, we should manage

delay(Driggin E, 2020).

early(De Luca G).

Elective operations including CABG (coronary

The duration between symptoms presentation

artery bypass graft) are being reduced or even

and FMC during the pandemic is remarkably

cancelled by many hospitals(Welt FGP, 2020),

delayed, and this decreases the benefits of

but this may lead to low quality of life as these

primary

individuals have symptoms and severe illness

percutaneous

individuals

with

ST

intervention
elevation

(PCI)in

myocardial

(Welt FGP, 2020).

infarction(Abdelaziz HK).

Despite that PPCI is the gold-standard therapy

The obvious increase of cardiac troponin 1 (ctn-

for

1) level in comparison to the same duration in

2018)thrombolytic

the previous year is mostly a result of late

recommended as the main reperfusion strategy

symptoms and long ischemia duration(Abdelaziz

in patients presenting with STEMI during the

HK). As well as these will lead to more newly

Coronavirus

diagnosed heart failure patients and deaths so

pandemic by many international statement (D.

this is another class of indirect complications of

Wang

the virus (Abdelaziz HK).

confrontation during PPCI has been cited as a

Also, evaluation of STEMI individuals after

significant route of infection transmission, and

arriving the hospitals is delayed and this is due

the high rate of transmission from asymptomatic

to many etiologies. To begin with, generalized

carriers underscores the significance of avoiding

infection of the surrounding environment can be

unnecessary procedures(D. Wang et al., 2020).

caused through positive pressure ventilation that

Moreover, medications for coronavirus interact

is present inside the catheterization rooms(C. K.

with famous cardiac ones(Driggin E, 2020).

Tam CF, Lam S, et al., 2020).

Antivirals can interact with anticoagulation

We should be so cautious prior to moving the

drugs,

patients to the catheterization laboratories,

antiarrhythmics.

through

including

Chloroquine/hydroxychloroquine interferes with

travelling, contacting COVID positive patients

β-blockers and antiarrhythmics (Driggin E,

and symptoms, as well as X-ray to the chest

2020), as bradycardia has been reported with

should be done.In spite of that , this may lead to

hydroxychloroquine and may be aggravated with

more delay in managing those patients (C. K.

beta-blockers (Talasaz et al., 2020).

Tam CF, Lam S, et al., 2020).

Regarding antiplatelets, Lopinavir is an antiviral

Proper

taking

detailed

history

postintervention

sterilization

ofeverything used for catheterization is very

Published by Mansoura Medical Journal, 2023

STEMI

et

patients,

therapy (TT)

Disease

al.,

antiplatelet

(Ibanez

2019

2020).

has

B,
been

(COVID-19)

Patient-physician

drugs,

statins,

and

drug used for this novel virus; it canincrease the
risk

of

bleeding

with

ticagrelor,

as

a
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consequence, it is contraindicated in patients

choice in those receiving fibrinolytic therapy

receiving lopinavir(Talasaz et al., 2020). In

(Wong et al., 2019).

patients without coagulopathy and bleeding risk,

Mechanisms of myocardial injury in COVID-

we can use prasugrel with lopinavir(Bikdeli et

19
This great effect on the cardiovascular

al., 2020).
For

anticoagulants, low molecular

weight

system is by multiple mechanisms including

heparin (LMWH) may have more merits than

direct

unfractionated

patients

inflammatory response, hypoxia, right heart

suffering from coagulopathy (Tang, Bai, et al.,

strain secondary to ARDS and lung injury, and

2020).

plaque rupture secondary to inflammation

If

heparin

the

(UFH)

in

cardiologist

postpones

angiography, LMWH can be used as the drug of

myocardial

damage,

systemic

(Bandyopadhyay et al., 2020)(figure 6).

Figure 6: mechanisms of myocardial injury due to coronavirus disease-2019 (Wei, Qian, Huang, & Geng, 2020).

1. Direct myocardial injury

order to bind with ACE2. When S protein binds

Direct myocardial injury—SARS-CoV-2 viral

to angiotensin converting enzyme 2,endocytosis

invasion of cardiomyocytes is thought to occur

of virus particles occurs(Li, Li, Farzan, &

by binding to ACE2,that can result in alteration

Harrison, 2005)and may result in down-

of its signaling pathways, leading to acute

regulation

myocardial and lung injury (Bansal, 2020).

cardiomyocytes, and the over-activation of renin

Host cells are invaded by SARS-CoV-2 through

angiotensin system.

S protein binding to ACE2(Hoffmann, Kleine-

An autopsy supports that theory by showing the

Weber, Schroeder, et al., 2020). There is protein

presence of the virus in the cardiomyoctes

on

associatedwith significant down-regulation of

the

cell

membrane

called

type

II

transmembrane serine proteases, its role is to cut
S protein andexpose the receptor-binding part in

https://mmj.mans.edu.eg/home/vol50/iss4/4
DOI: 10.21608/mjmu.2021.83010.1023

of

ACE2

expression

in

ACE2 expression (Oudit et al., 2009).
2. Hypoxia and ischemic injury
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Inflammation and dysfunction of the lungs

(disseminated intravascular coagulopathy)(Y.

caused by the virus decreases the oxygen–blood

Wang et al., 2020).

exchange, as a result of that, more hypoxemia,

4. Cytokine storm

low blood pressure and septic shock may

It means massive secretion of cytokines in

occur(Guan et al., 2019).Thus vital organs like

response to virus invasion and it contributes in a

the heart may not be supplied with sufficient

major way to the pathogenesis of myocardial

blood. At the same time, oxygen needed by the

injury.

heart is more because of fever that leads to

significantly high in patients with coronavirus

higher metabolic rate and as a consequence

disease

inflammation increases and the balance between

progression (Huang et al., 2020).

supplied

It is reported that Th2 anti-inflammatory

oxygen

and

that

consumed

is

Pro-inflammatory

2019

and

this

cytokines

indicates

are

disease

disturbed(Heusch, 2016).

cytokines, including IL-4 and IL-10, are

As the virus is progressing, this imbalance

elevated, and they are an indicator of disease

becomes more and moredue to several etiologies

seriousness(Chen et al., 2020). Those with no

including metabolic acidosis, fluid or electrolyte

symptoms had less cytokines than those with

disorder, and impairment of the neuro-humoral

symptoms, suggesting the pathogenicrole of

system (Tavazzi et al., 2020). Therefore,

cytokines (Long et al., 2020).

myocardial affection in coronavirus individuals

IL-6 is considered the major inflammatory

can be caused by indirect ways particularly in

cytokine and it is expressed in a very high levels

patients

in those with critical situations and suspected

with

already

diagnosed

heart

bad outcomes (Chen et al., 2020).it does not

diseases(Tao Guo et al., 2020).

only
3. Abnormal

coagulation

and

amplify

stimulatingthe

the

cytokine

production

of

storm
other

by
pro-

inflammatory cytokines but it encourages as

microcirculatory disturbance
Vascular endothelium can be attacked by

well the vascular leakage and interstitial oedema

COVID-19 in a direct manner, that leads to high

(Tanaka, Narazaki, & Kishimoto, 2016).

levels

in

Moreover, high troponin levels is significantly

disturbed

associated with elevated IL-6 in patients with

microcirculation(Hamming et al., 2004). In

coronavirus admitted to the hospitals (Wu et al.,

addition,

the

2020).All of this indicates that the main

microvasculature may lead to focal ischemic

contributor in cytokine storm to develop

changes and then AMI (Sugiura et al., 1977). A

myocardial injury is IL-6(Wei et al., 2020).

of

coagulation

expressed

ACE2,

abnormalities

disturbed

blood

resulting

and

flow

in

new study has proved that the incidence of
myocardial injury is more in those with DIC

Published by Mansoura Medical Journal, 2023
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Controversies regarding ACE inhibitors/

with ACEIs or ARBs in animal studies showed a

angiotensin receptor blockers

rise in the expression of ACE2(Ferrario et al.,

ACE2 is a receptor for COVID-19, physicians

2005).

are concerned about thedrugs that leads to its

In clinical studies, patients who use captopril

upregulation like ACE inhibitors and ARBs

(ACEI) for long duration (Luque, 1996) or

(angiotensin receptor blockers) which are used

olmesartan (ARB)(Furuhashi et al., 2015)had

for hypertension treatment,as it may have a

elevated angiotensin bloodlevels (Connors &

negative impact (Kuster et al., 2020). It was

Levy, 2020)or urinary levels of ACE2, that

proposed that this increase in ACE2 expression

indicateshighly active ACE2. On the contrary,

supports

COVID-19

patients with heart failure(Epelman et al., 2009),

severity(Bozkurt, Kovacs, & Harrington, 2020),

aortic stenosis(Ramchand et al., 2020), atrial

however, bad outcomes among patients were not

fibrillation(Walters et al., 2017) or coronary

linked to the use of these drugs (56). In addition

artery

to that, these drugs have no effect on the

Srivastava, Farouque, & Burrell, 2018)do not

COVID-19 infection susceptibility as it was

have ACE2 upregulation despite using RAS

found that there is no interaction between RAS

inhibitors .

(renin angiotensin system) blocking drugs and

Such conflicting results are mostly due to the

test

indirect effects of ACEIs or ARBs on ACE2,

the

positivity

greater

(Mancia,

Rea,

Ludergnani,

Apolone, & Corrao, 2020).

diseases

(CAD)(Ramchand,

Patel,

that rely on several conditions like ACE2

We have to discuss some major things.

baseline expression levels , doses and treatment

Starting with the debatable impact of RAS

duration. Second, no direct proof showed that

inhibitors on ACE2(Vaduganathan et al., 2020).

upregulation of ACE2 has an effect on

ACE and ACE2 are structurally similar but they

susceptibility to viral infection (Vaduganathan et

differ in their targets. ACE changes angiotensin

al., 2020).

I to angiotensin II, while ACE2 breaks

However, it is hardly recommended that

angiotensin II to angiotensin(P. Zhou et al.,

treatment for hypertension with ACEIs and

2020).

ARBs should be continued as there is no proved

Downstreaming of angiotensin II caused by

evidence to discontinue them during the

ACEIsand ARBs is due to prevention of

pandemic(de Simone, 2020).

angiotensin I to be converted to angiotensin II

Troponin elevation suggesting myocardial

by ACEIs, and blockage of angiotensin II

infarction in patients with COVID-19

receptor type 1 by ARBs (Vaduganathan et al.,

Those with previous CAD or even risk factors

2020). So, neither oneof these medications has a

for atherosclerosis have more susceptibility of

direct impact on ACE2. Despite that, treatment

developing acute coronary syndrome (ACS)

https://mmj.mans.edu.eg/home/vol50/iss4/4
DOI: 10.21608/mjmu.2021.83010.1023
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with any acute infection (Cheng et al., 2020)or

probability(Mahmud

inflammation. This might be as a consequence

2020).Moreover,more than half of the patients

of disturbed balance between oxygen supply and

need PCI after fibrinolysis, as a result of that,

demand (Smeeth et al., 2004).

longer hospital stay will be needed thus free

As well as, low oxygen in the blood may result

beds

in massive intracellularcalcium and as a

limited(Mahmud et al., 2020).

consequencedeath

cardiomyocytes(Zheng,

As well as, STEMI-mimickers are common in

Ma, Zhang, & Xie, 2020). Type 2 MI can be

COVID-19 including focal myocarditis or stress

caused due to CAD or even without, However,

cardiomyopathy(Madjid,

increased blood levels of troponin in coronavirus

Solomon, & Vardeny, 2020). Those patients did

patients may indicate type 2 myocardial

not get any benefits from fibrinolysis but it can

infarction as the pre-existing stable CAD is

increase the risk of bleeding and they may need

aggravated by the infection. Type 1 myocardial

catheterization for diagnosis. If staff and PPE

infarction can also be caused by this virus

are not available as well as catheterization

through

laboratories, a fibrinolysis first approach should

plaque

of

rupture

with

thrombus

formation(Thygesen et al., 2019).

for

et

coronavirus

al.,

patients

will

be

Safavi-Naeini,

be considered(Mahmud et al., 2020).

High troponin is considered as a good

These patients with STEMI should be evaluated

prognostic factor in coronavirus patients. High

first in the emergency department prior to

troponin at the beginning is associated with

catheterizationto make sure that appropriate

more severe disease (Oudkerk et al., 2020)

risks are assessed. Face mask is required for all

andmore ICU admissions.In addition to that,

patients to decrease the risk of contamination of

stratification of the risk of death is according to

the surrounding and infection spread. PPE

the level of troponin elevation and pre-existing

should be available to the people who will attend

CVD (S Shi et al., 2020).

the procedure especially an N95 respiratory

Management

mask(Mahmud et al., 2020). In addition, if there

a) Definite ST elevated myocardial infarction

is lung dysfunction, intubation should be

The main line of treatment for STEMI patients

achieved before arriving to the catheterization

within 90 minutes from FMC is primary

lab (Mahmud et al., 2020).

percutaneous coronary intervention, and it

On the other hand, FT (fibrinolytic therapy) is

should

recommended

remain

the

standard

during

the

in

China

over

PPCI

for

pandemic(Mahmud et al., 2020).

STEMI(Daniels, Cohen, Bavry, & Kumbhani,

Compared to fibrinolytics, Primary PCI isbetter

2020). Outcomes of FT in comparison to PPCI

for setting normal blood flow in the coronaries

were similar regarding death, shock, heart

as

failure,

well

as

it

has

Published by Mansoura Medical Journal, 2023

less

bleeding

or

reinfarction,

but

intracranial
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hemorrhage was higher with FT.If delays in

Conclusion

PPCI are unavoidable, a pharmacoinvasive

Coronavirus disease 2019 has a widespread

approach is not worse than PPCI(Daniels et al.,

impact on all body systems, not only the

2020).

respiratory, including the CV system. Cardiac

Timely PPCI depends mainly on systems of

injurymay occur through possible ischemic and

care, not just individual operators. PPCI

nonischemic mechanisms. The spike proteinand

treatment delays in the pandemic arise, even

ACE2 relationship is likely to have a major role

among those who are free from the virus. Thus,

in the pathogenesis of this illness,especially in

fibrinolysis in the emergency department may

CV symptoms.

lessen systems-based delays. A door-to-needle

CV biomarkers should be monitored essentially,

time of 30 minutes may have a better outcome

and we should diagnose early, and try to prevent

than a door-to-balloon time of 90 minutes as

myocardial dysfunction bythis novel virus.

early reperfusion is more important than the
mode of reperfusion (Daniels et al., 2020).

During this pandemic, the main line of
treatment of ST-elevation myocardial infarction
is primary PCI while for non ST-elevation

b) Possible ST elevated myocardial infarction

myocardial infarction patients who areaffected

If the diagnosis is not sure due to atypical

by coronavirus are mainly managedwith an

presentation, these patients should be evaluated

initial medical treatment.

in the ED (Mahmud et al., 2020).

This

evaluation relies on two items: (a) stratifying the
risk for coronavirus disease 2019 and (b) more
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